The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new...
There are valid points in the short report, but it may present a buying opportunity for long-term investors....
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space....
Sam Koppelman, Hunterbrook Media publisher and co-founder, joins 'Closing Bell Overtime' to talk its report that Hims & Hers' GLP-1 offering is a 'knockoff' drug form 'shady supplier'....
A short report was published that makes a case against Hims & Hers' new GLP-1 product. The report was put out by a media organization with ties to a fund that is also a short-seller of the stock....
Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an interesting business model, as it publishes...
Consumer spending on healthcare and restaurants is resilient in a range of economic environments. Hims & Hers is tapping into the potential of the lucrative telehealth market....
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day....
The telehealth company is offering innovative products at lower prices....